Literature DB >> 15532706

Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines.

Lineng Zhang1, Qiang Yu, Jianyu He, Xiliang Zha.   

Abstract

The tumor suppressor PTEN gene maps to chromosome 10q23.3 and encodes a dual specificity phosphatase. Mutations of this gene had been found in a variety of human tumors. In the present study, we analyzed the structure and expression of the PTEN gene in 34 hepatocellular carcinoma tissues and two hepatoma cell lines. We found neither homozygous nor hemizygous deletions in these samples. We, however, found point mutations in 4 of the 34 tissue samples. Five of ten hepatocellular carcinoma tissues showed reduced PTEN expression at mRNA level. HepG2 and SMMC-7721 hepatoma cells showed decreased PTEN expression at both mRNA and protein levels compared with immortalized L02 hepatic cells. PTEN mRNA in SMMC-7721 hepatoma cells could be reduced by TGF-betaI treatment. We also found that the phosphorylation levels of FAK in both of the hepatoma cell lines were higher than that in L02 hepatic cells. Transient expression of the PTEN gene in SMMC-7721 and HepG2 hepatoma cells resulted in decreased FAK phosphorylation. The level of FAK tyrosine phosphorylation appeared to be inversely correlated with the level of the PTEN protein. In summary, our results indicated that the function of the PTEN gene in hepatocarcinomas may be impaired mainly through point mutations and expression deficiency and that the defect of PTEN in tumor cells could alter the phosphorylation of FAK.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15532706     DOI: 10.1023/b:mcbi.0000038212.78008.7f

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  39 in total

1.  Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers.

Authors:  Y Yaginuma; T Yamashita; T Ishiya; A Morizaki; Y Katoh; T Takahashi; H Hayashi; M Ishikawa
Journal:  Mol Carcinog       Date:  2000-02       Impact factor: 4.784

2.  PTEN germ-line mutations in juvenile polyposis coli.

Authors:  S Olschwang; O M Serova-Sinilnikova; G M Lenoir; G Thomas
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

3.  Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.

Authors:  M M Georgescu; K H Kirsch; P Kaloudis; H Yang; N P Pavletich; H Hanafusa
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas.

Authors:  M P Butler; S I Wang; R S Chaganti; R Parsons; R Dalla-Favera
Journal:  Genes Chromosomes Cancer       Date:  1999-04       Impact factor: 5.006

5.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

6.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

Authors:  P Guldberg; P thor Straten; A Birck; V Ahrenkiel; A F Kirkin; J Zeuthen
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

7.  PTEN/MMAC1 mutations in endometrial cancers.

Authors:  J I Risinger; A K Hayes; A Berchuck; J C Barrett
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

8.  Promoter methylation and silencing of PTEN in gastric carcinoma.

Authors:  Young-Hwa Kang; Hye Seung Lee; Woo Ho Kim
Journal:  Lab Invest       Date:  2002-03       Impact factor: 5.662

9.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function.

Authors:  M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

10.  Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1.

Authors:  M P A Ebert; G Fei; L Schandl; C Mawrin; K Dietzmann; P Herrera; H Friess; T M Gress; P Malfertheiner
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

View more
  7 in total

1.  PTEN in liver diseases and cancer.

Authors:  Marion Peyrou; Lucie Bourgoin; Michelangelo Foti
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 2.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

3.  Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome.

Authors:  Marta S Sarquis; Shipra Agrawal; Lei Shen; Robert Pilarski; Xiao-Ping Zhou; Charis Eng
Journal:  Am J Hum Genet       Date:  2006-05-22       Impact factor: 11.025

4.  Expression of focal adhesion genes in mesenchymal stem cells under simulated microgravity.

Authors:  A Yu Ratushnyy; L B Buravkova
Journal:  Dokl Biochem Biophys       Date:  2018-01-03       Impact factor: 0.788

Review 5.  The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers.

Authors:  Qinyi Wang; Junmin Wang; Hongjiao Xiang; Peilun Ding; Tao Wu; Guang Ji
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

6.  Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation.

Authors:  Hirozumi Sawai; Yuji Okada; Hitoshi Funahashi; Yoichi Matsuo; Hiroki Takahashi; Hiromitsu Takeyama; Tadao Manabe
Journal:  Mol Cancer       Date:  2005-10-06       Impact factor: 27.401

7.  Association of PTEN expression with liver function and inflammatory changes in patients with liver cancer after chemotherapy.

Authors:  Jixiang Zhou; Xiaoli Li
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.